We carried out a genome-wide association study among Chinese women to identify risk variants for breast cancer. After analyzing 607,728 SNPs in 1,505 cases and 1,522 controls, we selected 29 SNPs for a fast-track replication in an independent set of 1,554 cases and 1,576 controls. We further investigated four replicated loci in a third set of samples comprising 3,472 cases and 900 controls. SNP rs2046210 at 6q25.1, located upstream of the gene encoding estrogen receptor a (ESR1), showed strong and consistent association with breast cancer across all three stages. Adjusted odds ratio (95% CI) were 1.36 (1.24-1.49) and 1.59 (1.40-1.82), respectively, for genotypes A/G and A/A versus G/G (P for trend 2.0 Â 10 À15 ) in the pooled analysis of samples from all three stages. We also found a similar, albeit weaker, association in an independent study comprising 1,591 cases and 1,466 controls of European ancestry (P trend ¼ 0.01). These results strongly implicate 6q25.1 as a susceptibility locus for breast cancer.
Breast cancer, a complex multifactorial disease, is one of the most common malignancies among women worldwide. Genetic factors have an important role in the pathogenesis of both sporadic and familial breast cancer [1] [2] [3] . However, only a small fraction of breast cancer cases can be explained by the breast cancer susceptibility genes identified thus far, such as the BRCA1 and BRCA2 genes [4] [5] [6] . Familybased linkage studies have been successful in mapping genes associated with mendelian disorders [1] [2] [3] 7 . However, this approach has had limited success in identifying common genetic variants that confer small-tomoderate risk of disease susceptibility.
Over the past 15 years, numerous association studies have evaluated variants in many candidate genes in relation to breast cancer risk [1] [2] [3] [7] [8] [9] . Although many variants have been implicated, only a few have been replicated in subsequent studies 10, 11 . Four recent genomewide association (GWA) studies have identified several new risk alleles for breast cancer [12] [13] [14] [15] . All these studies, however, were conducted in women of European descent, who differ from women of other ancestry groups in certain aspects of their genetic architecture. Therefore, additional GWA studies, particularly those conducted in populations of non-European descent, are needed to fully uncover the genetic basis of breast cancer susceptibility.
Since 1996, we have initiated multiple population-based epidemiological studies of cancer in Shanghai, China, including the Shanghai Breast Cancer Study (SBCS) (Supplementary Methods online). Included in stages 1 to 3 of the current GWA study were genomic DNA samples from 6,531 incident breast cancer cases and 3,998 community controls who participated in these studies ( Table 1) . We initiated the pilot phase of the GWA study in 2005 with 150 cases and 150 controls genotyped using the Affymetrix GeneChip Human Mapping 500K Array Set, which contains approximately 500,000
SNPs. An additional 1,374 cases and 1,402 controls were genotyped in 2008 using the Affymetrix Genome-Wide Human SNP Array 6.0, which contains 906,602 SNPs. Cases and controls were matched on age. Included in the current analysis were 607,728 SNPs in the Affymetrix SNP array 6.0 and 330,885 SNPs in the Affymetrix 500K array set that met the following criteria: (i) Z5% minor allele frequency (MAF), (ii) Z95% call rate and (iii) Z95% genotyping concordance rate in quality control samples; additionally, for SNPs in the Affymetrix 500K arrays, only those that are also present in the Affymetrix 6.0 array were included (Supplementary Table 1 online) . Of the initial 3,076 samples included in the GWA scan, 49 samples were excluded owing to o95% call rate (n ¼ 4) or sample duplication or contamination (n ¼ 45). A total of 1,505 cases and 1,522 controls remained for the GWA analyses. Multidimensional scaling analyses based on pairwise identity by state showed no evidence of apparent genetic admixture in this study population ( Supplementary  Fig. 1 online) .
Multiple genomic locations were shown to be potentially associated with breast cancer risk (Fig. 1) , and the observed number of SNPs with a small P value is larger than expected by chance ( Supplementary Fig. 2 online) . We obtained similar results after excluding the 292 subjects genotyped by Affymetrix 500K Array Set from the analyses (data not shown). P values presented in Figure 1 are derived from trend tests using logistic regression (d.f. ¼ 1) after adjustment for age. Of the 11 SNPs previously identified from published GWA studies for breast cancer [12] [13] [14] [15] , six are included in the Affymetrix 6.0 array, and four of them showed an association with breast cancer risk in our dataset consistent with that reported previously (Supplementary Table 2 online). Specifically, elevated risk of breast cancer was found to be associated with the minor alleles of rs1219648 (FGFR2, P trend ¼ 0.0025), rs2981582 (FGFR2, P trend ¼ 0.001), rs3803662 (TOX3, P trend ¼ 0.012) and rs8051542 (TOX3, P trend ¼ 0.098). No apparent association was found for rs3817198 (LSP1, P trend ¼ 0.75), and the association with rs2180341 (6q22.33, P trend ¼ 0.068) was in the opposite direction of the one reported initially in a study based on the Ashkenazi Jewish population 15 .
For our fast-track replication, we genotyped the 29 most promising SNPs in an independent set of 1,554 cases and 1,576 controls recruited in the SBCS. These SNPs were selected from those that had (i) MAF Z 10%; (ii) very clear genotyping clusters; (iii) not been confirmed previously as a genetic risk variant for breast cancer; and (iv) P r 1 Â 10 À4 for all samples along with a consistent association at P r 0.05 in samples analyzed in the first batch (754 cases, 741 controls) and the second batch (751 cases, 781 controls) or P r 5 Â 10 À4 for all subjects and consistent association at P r 0.01 in both batches.
Of the 29 SNPs included in fast-track replication (Supplementary Table 3 online), four SNPs in stage 2 showed a significant association with breast cancer risk at P r 0.05 and a fifth had a P value of 0.077 ( Table 2) . A highly significant association with breast cancer risk was identified for rs2046210 (P ¼ 3.9 Â 10 À5 ) and rs10872676 (P ¼ 1.6 Â 10 À3 ). Both SNPs are located at 6q25.1, approximately 4.4 kb apart, and show a high degree of linkage disequilibrium (LD; r 2 ¼ 0.69). We selected rs2046210 for further validation, as rs10872676 showed a weaker association with breast cancer risk than rs2046210, and its association was not statistically significant after adjustment for rs2046210.
We further evaluated four SNPs in stage 3 ( Table 2) , which included 3,472 cases who were recruited during 2002 and 2006 as part of the Shanghai Breast Cancer Survivor Study (SBCSS), along with 900 healthy women recruited from the same source population as the control group for a population-based endometrial cancer study that was conducted in parallel with the SBCS. Again, rs2046210 was associated with breast cancer risk (P ¼ 3.3 Â 10 À7 ) ( Table 2) , and the P value reached 2.0 Â 10 À15 in the pooled analysis of samples from all three stages (Table 3) . This P value is substantially lower than the genome-wide significance level based on conservative Bonferroni adjustment of multiple comparisons at a level a ¼ 0.05, providing unequivocal evidence for an association of this SNP with breast cancer risk. This SNP was associated with a population attributable risk of Chr. 2
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Chr. X Figure 1 Genome-wide association results in the Shanghai Breast Cancer Study. Scatter plot of P values in log-scale from the trend test for 607,728 genotyped SNPs comparing 1,505 cases and 1,522 controls. 18.9% and an estimated 2.1% excess familial risk of breast cancer. The positive association of this SNP with breast cancer risk was found for both pre-and postmenopausal women, and the association was stronger for estrogen receptor (ER)-negative cancer than ER-positive cancer (P ¼ 0.02) ( Table 3) . None of the other three SNPs were replicated in stage 3 ( Table 2 ). Figure 2 shows the 6q25.1 locus where rs2046210 is located. A cluster of SNPs that are in strong LD with rs2046210 all showed a significant association with breast cancer risk with P r 0.001 in stage 1. Using data from stage 1, haplotype analyses of an LD block including rs2046210 and seven other SNPs as defined by the method of Gabriel et al. 16 , or a larger block including seven additional SNPs, failed to identify any particular SNP that may explain the observed association at this locus (Supplementary Table 4 online).
We also evaluated rs2046210 in association with breast cancer risk among 1,590 cases and 1,466 controls of European ancestry, recruited as part of the Nashville Breast Health Study (NBHS), a populationbased case-control study conducted in Tennessee, United States ( Table 1) . Consistent with the findings from the Shanghai studies, the variant allele of this SNP was associated with an elevated risk of breast cancer, and the association was stronger in post-than premenopausal women ( Table 4) .
Several genes are located in the 1-Mb region centered on rs2046210, including PLEKHG1, MTHFD1L, AKAP12, ZBTB2, RMND1, C6orf211, C6orf97, ESR1, C6orf98, SYNE1 and NANOGP11. Of them, ESR1 is of particular interest to breast carcinogenesis. ESR1 encodes estrogen receptor a (ERa), which regulates signal transduction of estrogen, a sex hormone that has a central role in the etiology of breast cancer. Elevated estrogen levels have been shown to be associated with an increased risk of breast cancer in multiple prospective studies 17 . Because the biological effects of estrogen are mediated primarily through high-affinity binding to ERs, genetic variants in ER genes, including ESR1 and ESR2, have been the focus of multiple previous epidemiologic studies [18] [19] [20] [21] . The identified SNP (rs2046210) associated with breast cancer risk is located 29 kb upstream of the first untranslated exon and 180 kb upstream of the transcription start site of exon 1 of the ESR1 gene 22 . None of the SNPs at this locus have been previously reported to be associated with breast cancer, nor is rs2046210 in LD with two of the most widely studied polymorphisms in ESR1: rs2234693 and rs9340799 (r 2 o 0.05 in both HapMap Asian and European-descent samples). rs2234693 was genotyped in stage 1 of the current study and carried an OR (95% CI) of 0.95 (0.80-1.12) for C/T and 0.79 (0.63-1.00) for T/T genotype in relation to breast cancer risk. Because of the relatively close location to ESR1 and the biological function of ERa, it is possible that rs2046210 or SNPs in LD with it may alter ESR1 expression and affect susceptibility to breast cancer. It is noteworthy that a recent GWA study has found that the 6q25.1 locus is associated with bone mineral density 23 , a phenotype that is affected by estrogen. rs2046210 is located 6 kb downstream of C6orf97, the function of which is unknown. The LD block that includes rs2046210 spans a region of 41 kb (151,971,942 to 152,013,380) that contains part of C6orf97. By running BLAST with C6orf97 coding peptide as the query sequence, we found a structural maintenance of chromosomes (SMC) domain in the C terminus of the C6orf97 protein. SMC proteins seem to have important roles in chromosome dynamics 24 . Further research into the function of C6orf97 and its potential association with breast cancer may be warranted.
METHODS
Study population. For detailed descriptions of the component studies, see Supplementary Methods. The study protocol was approved by the institutional review boards of the Vanderbilt University Medical Center, the Shanghai Cancer Institute, the Shanghai Center for Disease Prevention and Control, and Meharry Medical College. Informed consent was obtained from all participants.
Genotyping and quality control procedures. For detailed descriptions of the genotyping and quality control procedures, see Supplementary Methods. Briefly, in stage 1, the initial 300 subjects were genotyped using the Affymetrix GeneChip Mapping 500K Array Set and the remaining 2,776 samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. In each of the 96-well plates genotyped using the Affymetrix SNP 6.0 array, three positive quality control samples (NA15510, NA10851 and NA18505) purchased from Coriell Cell Repositories and a negative quality control sample (water) were included. SNP data obtained from the positive quality control samples showed a very high concordance rate of called genotypes based on 79,764,872 comparisons (mean, 99.87%; median, 100%). In addition, 742 SNPs were genotyped using the Affymetrix Target Genotyping System, TaqMan or Sequenom for a subset of subjects included in previous studies. A high concordance rate was also observed between genotypes determined using these platforms and Affymetrix SNP Array 6.0 based on 1,478,383 comparisons (mean, 99.1%; median, 99.8%). Samples with genotyping call rates less than 95% were excluded, and the remaining samples were recalled by using Birdseed v2. The sex of all study samples was confirmed to be female. The identity-bydescent analysis based on identity by state was done to detect first-degree cryptic relationships using the PLINK version 1.04 (ref. 25) . The final dataset included 3,027 individuals and 607,728 markers in the Affymetrix SNP Array 6.0 and 330,885 in the Affymetrix 500K Array Set that met the following criteria: (i) genotype call rate Z95%; (ii) MAF Z5%; and (iii) genotyping concordance rate in quality control samples Z95%. Also excluded from the analyses were 21,223 SNPs that are on Affymetrix 500K Array Set but not on the SNP Array 6.0. Genotyping for the replication sets was completed using the iPLEX Sequenom MassArray platform. Included in each 96-well plate as quality control samples were two negative controls (water), two blinded duplicates and two samples included in the HapMap project. The mean concordance rate was 99.7% for blind duplicates (2,572 comparisons) and 99.2% for HapMap samples (1,751 comparisons).
Statistical analyses. PLINK version 1.04 was used to analyze genome-wide data obtained in stage 1. A set of 4,305 SNPs with MAF Z .35 and Z100 kb between two adjacent SNPs was selected to evaluate the population structure. The inflation factor l was estimated to be 1.024, suggesting that population substructure, if present, should not have any appreciable effect on the results. Odds ratios (OR) and 95% confidence intervals (CI) were estimated from logistic regression analysis. Age was adjusted in the GWA analyses of stage 1 data to select promising SNPs. Additional adjustment was made for 26 . Haplotype blocks were defined using the methods of Gabriel et al. 16 and nine blocks were observed (Supplementary Fig. 3 online) . Block 5 includes rs2046210 and seven other SNPs: rs7740686, rs7763637, rs9397436, rs9397437, rs6908732, rs852004 and rs865898 (Supplementary Table 4 ). We analyzed associations of haplotypes with breast cancer risk with HAPSTAT software 27 using additive models. Additional analyses were done for haplotypes defined using SNPs included in blocks 4 and 5 with a total of 15 SNPs ( Supplementary Fig. 3 and Supplementary Table 4) .
For imputation analysis, we used PLINK to impute genotypes for autosomal SNPs that were present in HapMap Phase II release 23a but not genotyped in our GWA scan. HapMap genotype data from the 90 Asian HapMap subjects that have MAF Z 1% and genotyping rate Z95% were used as reference. During the imputation, an information score was generated for each imputed SNP that reflected how confidently genotypes were inferred. Values below 0.80 were taken to be indicative of poor quality and were not analyzed. Besides the 0.61 million observed SNPs, an additional 1.14 million imputed SNPs were tested for association with breast cancer.
URLs. PLINK, http://pngu.mgh.harvard.edu/purcell/plink.
Note: Supplementary information is available on the Nature Genetics website.
